We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at ...

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up ...

Wedbush analyst David Nierengarten maintained a Buy rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of ...

Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Stock analysts at Wedbush lowered their Q1 2025 earnings estimates for Blueprint Medicines in a research report issued on Wednesday ...

Blueprint Medicines Stock Performance BPMC stock opened at $80.84 on Monday. The firm has a 50 day simple moving average of $90.91 and a 200 day simple moving average of $93.54. Blueprint ...

Blueprint Medicines' primary revenue driver is Ayvakit, approved for various forms of Systemic Mastocytosis (SM) and showing strong growth, with 2024 revenues at $479m. The company projects ...

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, ...

Headquartered in Massachusetts, Blueprint Medicines Corporation (NASDAQ:BPMC) is a precision therapy company focusing on genomically defined cancers and hematologic diseases. Their marketed ...